Different flecainide sensitivity of hNav 1.4 channels and myotonic mutants explained by state-dependent block

Journal of Physiology

Volumn 554, Issue 2, 2004, Pages 321-334

  Desaphy, Jean François ^a   Luca, Annamaria D E ^a   Didonna, Maria Paola ^a   George Jr , Alfred L ^b   Camerino, Diana Conte ^a  

^a UNIVERSITY OF BARI   (Italy)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; FLECAINIDE; MEXILETINE; VOLTAGE GATED SODIUM CHANNEL; SODIUM CHANNEL NAV1.4; VOLTAGE DEPENDENT ANION CHANNEL;

ARTICLE; BINDING AFFINITY; CALCULATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MATHEMATICAL COMPUTING; MOLECULAR MECHANICS; MUSCLE CELL; PRIORITY JOURNAL; RECEPTOR BLOCKING; SKELETAL MUSCLE; SODIUM CURRENT; THOMSEN DISEASE; ACTION POTENTIAL; BINDING SITE; CELL MEMBRANE DEPOLARIZATION; DRUG PROTEIN BINDING; EXPRESSION VECTOR; HYPERPOLARIZATION; MOLECULAR INTERACTION; MYOTONIA; POTASSIUM AGGRAVATED MYOTONIA; PROTEIN EXPRESSION;

DOSE-RESPONSE RELATIONSHIP, DRUG; FLECAINIDE; HUMANS; ION CHANNEL GATING; MUSCLE PROTEINS; MUTATION; MYOTONIA; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 0842344628     PISSN: 00223751     EISSN: None     Source Type: Journal    
DOI: 10.1113/jphysiol.2003.046995     Document Type: Article

References (46)

1. Abriel H, Wehrens XHT, Benhorin J, Kerem B & Kass RS (2000). Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome. Circulation 102, 921-925.
2. American Heart Association (2000). International guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6: Advanced Cardiovascular Life Support: Section 5: Pharmacology I: Agents for Arrhythmias. Circulation 102, I112-I128.
3. Anno T & Hondeghem LM (1990). Interactions of flecainide with guinea pig cardiac sodium channels. Importance of activation unblocking to the voltage-dependence of recovery. Circ Res 66, 789-803.
4. Bean BP, Cohen CJ & Tsien RW (1983). Lidocaine block of cardiac sodium channels. J General Physiol 81, 613-642.
5. Bendahhou S, Cummins TR, Kwiecinski H, Waxman SG & Ptacek LJ (1999). Characterization of a new sodium channel mutation at arginine 1448 associated with moderate paramyotonia congenita in humans. J Physiol 518, 337-344.
6. Benhorin J, Taub R, Goldmit M, Kerem B, Kass RS, Windman I & Medina A (2000). Effects of flecainide in patients with new SCN5A mutation. Mutation-specific therapy for long-QT syndrome? Circulation 101, 1698-1706.
7. Cannon SC (2001). Voltage-gated ion channelopathies of the nervous system. Clin Neurosci Res 57, 772-779.
8. + channel fast inactivation. Neuron 22, 73-87.
9. Desaphy J-F, De Luca A, Tortorella P, De Vito D, George AL Jr & Conte Camerino D (2001). Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative. Neurology 57, 1849-1856.
10. Desaphy J-F, Pierno S, De Luca A, Didonna D & Conte Camerino D (2003). Different ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders. Mol Pharmacol 63, 659-670.
11. + channels expressed in a mammalian cell line. J Physiol 496, 275-286.
12. + channel mutation causing paramyotonia congenita. Pflugers Arch 436, 757-765.
13. Frazier DT, Narahashi T & Yamada M (1970). The site of action and active form of local anesthetics. Experiments with quaternary compounds. J Pharmacol Exp Ther 171, 45-51.
14. Grant AO, Chandra R, Keller C, Carboni M & Starmer CF (2000). Block of wild-type and inactivation-deficient cardiac sodium channels IFM/QQQ stably expressed in mammalian cells. Biophys J 79, 3019-3035.
15. Griggs RC & Ptácek LJ (1999). Mutations of sodium channels in periodic paralysis. Can they explain the disease and predict treatment? Neurology 52, 1309-1310.
16. Groome JR, Fujimoto E, George AL Jr & Ruben PC (1999). Differential effects of homologous S4 mutations in human skeletal muscle sodium channels on deactivation gating from open and inactivated states. J Physiol 516, 687-698.
17. Hayward LJ, Sandoval GM & Cannon SC (1999). Defective slow inactivation of sodium channels contributes to familial periodic paralysis. Neurology 52, 1447-1453.
18. Hilber K, Sandtner W, Kudlacek O, Schreiner B, Glaser I, Schütz W, Fozzard HA, Dudley SC & Todt H (2002). Interactions between fast and ultra-slow inactivation in the voltage-gated sodium channel. J Biol Chem 277, 37105-37115.
19. Hille B (1977). Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J General Physiol 69, 497-515.
20. Ji S, George AL Jr, Horn R & Barchi RL (1996). Paramyotonia congenita mutations reveal different roles for segments S3 and S4 of domain D4 in hNav1.4 sodium channel gating. J General Physiol 107, 183-194.
21. Jurkat-Rott K, Lerche H & Lehmann-Horn F (2002). Skeletal muscle channelopathies. J Neurol 249, 1493-1502.
22. + channels must deactivate to recover from inactivation. Neuron 12, 819-829.
23. + channels: Evidence from experiments with neutral and quaternary flecainide analogues. J General Physiol 121, 199-214.
24. + channels by flecainide: evidence from the analysis of disease-linked mutations. J General Physiol 120, 39-51.
25. Moran O, Nizzari M & Conti F (1999). Myopathic mutations affect differently the inactivation of the two gating modes of sodium channels. J Bioenerg Biomembr 31, 591-608.
26. Moxley RT (2000). Channelopathies. Curr Treatment Opt Neurol 2, 31-47.
27. Nagatomo T, January CT & Makielski JC (2000). Preferential block of late sodium current in the LQT3 ÄKPQ mutant by the class Ic antiarrhythmic flecainide. Mol Pharmacol 57, 101-107.
28. Nitta J-I, Sunami A, Marumo F & Hiraoka M (1992). States and sites of actions of flecainide on guinea-pig cardiac sodium channels. Eur J Pharmacol 214, 191-197.
29. Nuss HB, Kambouris NG, Marban E, Tomaselli GF & Balser JR (2000). Isoform-specific lidocaine block of sodium channels explained by differences in gating. Biophys J 78, 200-210.
30. Nuss HB, Tomaselli GF & Marban E (1995). Cardiac sodium channels (hH1) are intrinsically more sensitive to tonic block by lidocaine than are skeletal muscle (μ1) channels. J General Physiol 106, 1193-1210.
31. + channel. Proc Natl Acad Sci U S A 92, 11839-11843.
32. + channels. Proc Natl Acad Sci U S A 93, 9270-9275.
33. Rosenfeld J, Sloan-Brown K & George AL Jr (1997). A novel muscle sodium channel mutation causes painful congenital myotonia. Ann Neurol 42, 811-814.
34. Sheets MF & Hanck DA (1999). Gating of skeletal and cardiac muscle sodium channels in mammalian cells. J Physiol 514, 425-436.
35. Sheets MF & Hanck DA (2003). Molecular action of lidocaine on the voltage sensors of sodium channels. J General Physiol 121, 163-175.
36. + channel. J Physiol 537, 701-714.
37. Vaughan Williams EM (1984). Subgroups of class I antiarrhythmic drugs. Eur Heart J 5, 96-98.
38. Vilin YY & Ruben PC (2001). Slow inactivation in voltage-gated sodium channels: molecular substrates and contributions to channelopathies. Cell Biochem Biophys 35, 171-190.
39. Viswanathan PC, Bezzina CR, George AL Jr, Roden DM, Wilde AAM & Balser JR (2001). Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. Circulation 104, 1200-1205.
40. + channel subtypes. Biophys J 70, 1700-1708.
41. Wang DW, VanDeCarr D, Ruben PC, George AL Jr & Bennett PB (1999). Functional consequences of a domain I/S6 segment sodium channel mutation associated with painful congenital myotonia. FEBS Lett 448, 231-234.
42. Weckbecker K, Würz A, Mohammadi B, Mansuroglu T, George AL Jr, Lerche H, Dengler R, Lehmann-Horn F & Mitrovic N (2000). Different effects of mexiletine on two mutant sodium channels causing paramyotonia congenita and hyperkalemic periodic paralysis. Neuromuscul Disord 10, 31-39.
43. Weiser T, Qu Y, Catterall WA & Scheuer T (1999). Differential interaction of R-mexiletine with the local anesthetic receptor site on brain and heart sodium channel α-subunits. Mol Pharmacol 56, 1238-1244.
44. Wright SN, Wang S-Y, Kallen RG & Wang GK (1997). Differences in steady-state inactivation between Na channel isoforms affect local anesthetic binding affinity. Biophys J 73, 779-788.
45. Yang N, Ji S, Zhou M, Ptacek LJ, Barchi RL, Horn R & George AL Jr (1994). Sodium channel mutations in paramyotonia congenita exhibit similar biophysical phenotypes in vitro. Proc Natl Acad Sci U S A 91, 12785-12789.
46. Zhou JY, Potts JF, Trimmer JS, Agnew WS & Sigworth FJ (1991). Multiple gating modes and the effect of modulating factors on the m1 sodium channel. Neuron 7, 775-785.